PET/CT accurately assesses breast cancer patients after neodjuvant chemo

November 29, 2012

FDG-PET/CT is useful in the evaluation of neoadjuvant chemotherapy (NAC) efficacy and in management of locally advanced breast cancer patients, according to a single-center study presented Nov. 25 at the 2012 Radiological Society of North America (RSNA).

In her presentation, the study’s lead author Sachiko Kiyoto, MD, said, that “the predictive and prognostic assessment [of FDG-PET in these patients] is controversial, even now.” Thus, she and her colleagues from the Shikoku Cancer Center in Matsuyama City, Japan, sought to evaluate whether changes in FDG tumor uptake at baseline and after NAC could predict pathological complete response (pCR) and disease-free survival after surgery.